Archive · 17 Dec 2025
Senores Pharma Sees Strong Growth from Apnar Deal
Senores Pharmaceuticals is expecting a lot of growth from a deal they made with Apnar.
The company's leader, Swapnil Shah, said that the market for the five new medicines they are making could be worth $700 million.
They hope to make $15–18 million from these medicines over time.
By the end of the financial year 2028, they think they can make ₹250 crore in total revenue.
This is great news for the company and shows they are doing well in the medicine market.
Senores Pharmaceuticals expects strong growth from the Apnar deal.
The total market opportunity for the five ANDAs is estimated at $700 million.
The company targets net revenues of $15–18 million from these products over time.
Senores Pharma aims to achieve ₹250 crore in revenue by FY28.
Swapnil Shah, the company's Managing Director, highlighted the growth potential.
- Who
- Senores Pharmaceuticals
- What
- Strong growth from Apnar deal
- When
- By FY28
- Where
- Not specified
- Why
- Targeting net revenues from five ANDAs
- Company
- Senores Pharmaceuticals
- Deal
- Apnar deal
- Revenue Target
- ₹250 crore by FY28
- Market Opportunity
- $700 million for five ANDAs
- Revenue Target for ANDAs
- $15–18 million